This site is intended for healthcare professionals
  • Home
  • /
  • Guidelines
  • /
  • Mycoses
  • /
  • ESCMID and ECMM joint clinical guidelines for the ...
Guideline

ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013

Read time: 1 mins
Last updated:30th Jan 2014

These European Society for Clinical Microbiology and Infectious Diseases and European Confederation of Medical Mycology Joint Clinical Guidelines focus on the diagnosis
and management of mucormycosis. Only a few of the numerous recommendations can be summarized here. To diagnose mucormycosis, direct microscopy preferably using
optical brighteners, histopathology and culture are strongly recommended. Pathogen identification to species level by molecular methods and susceptibility testing are
strongly recommended to establish epidemiological knowledge. The recommendation for guiding treatment based on MICs is supported only marginally. Imaging is strongly
recommended to determine the extent of disease. To differentiate mucormycosis from aspergillosis in haematological malignancy and stem cell transplantation recipients,
identification of the reverse halo sign on computed tomography is advised with moderate strength. For adults and children we strongly recommend surgical debridement in
addition to immediate first-line antifungal treatment with liposomal or lipid-complex amphotericin B with a minimum dose of 5 mg/kg/day. Amphotericin B deoxycholate is
better avoided because of severe adverse effects. For salvage treatment we strongly recommend posaconazole 4 9 200 mg/day. Reversal of predisposing conditions is
strongly recommended, i.e. using granulocyte colony-stimulating factor in haematological patients with ongoing neutropenia, controlling hyperglycaemia and ketoacidosis in
diabetic patients, and limiting glucocorticosteroids to the minimum dose required. We recommend against using deferasirox in haematological patients outside clinical trials,
and marginally support a recommendation for deferasirox in diabetic patients. Hyperbaric oxygen is supported with marginal strength only. Finally, we strongly recommend
continuing treatment until complete response demonstrated on imaging and permanent reversal of predisposing factors.

 

Read full guideline